Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,295 JPY | +4.20% | +6.84% | -4.24% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.24% | 2.72B | C+ | ||
-2.31% | 187B | C+ | ||
-3.20% | 106B | C | ||
-5.04% | 66.9B | A | ||
+0.20% | 49.45B | B- | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.07% | 26.48B | B | ||
+2.36% | 26.25B | A- | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 2784 Stock
- Ratings Alfresa Holdings Corporation